Wall Street analysts expect Agios Pharmaceuticals Inc (NASDAQ:AGIO) to report sales of $16.11 million for the current fiscal quarter, Zacks Investment Research reports. Five analysts have provided estimates for Agios Pharmaceuticals’ earnings. The highest sales estimate is $20.10 million and the lowest is $13.80 million. Agios Pharmaceuticals reported sales of $11.36 million in the same quarter last year, which indicates a positive year-over-year growth rate of 41.8%. The firm is expected to report its next earnings results before the market opens on Thursday, November 1st.
On average, analysts expect that Agios Pharmaceuticals will report full year sales of $85.89 million for the current fiscal year, with estimates ranging from $81.93 million to $95.10 million. For the next year, analysts anticipate that the firm will report sales of $113.34 million, with estimates ranging from $79.28 million to $140.50 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that cover Agios Pharmaceuticals.
Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($1.19) EPS for the quarter, beating the consensus estimate of ($1.62) by $0.43. The business had revenue of $40.40 million during the quarter, compared to analysts’ expectations of $12.47 million. Agios Pharmaceuticals had a negative return on equity of 51.71% and a negative net margin of 462.08%. The company’s quarterly revenue was up 257.5% compared to the same quarter last year. During the same period last year, the firm earned ($1.78) EPS.
AGIO opened at $66.88 on Friday. The company has a market capitalization of $4.15 billion, a PE ratio of -9.96 and a beta of 1.73. Agios Pharmaceuticals has a 12 month low of $51.62 and a 12 month high of $99.82.
In related news, insider Scott Biller sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, August 6th. The stock was sold at an average price of $80.11, for a total value of $240,330.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director John Maraganore sold 13,555 shares of the firm’s stock in a transaction that occurred on Tuesday, September 11th. The shares were sold at an average price of $72.75, for a total value of $986,126.25. Following the completion of the transaction, the director now directly owns 38,609 shares of the company’s stock, valued at $2,808,804.75. The disclosure for this sale can be found here. Insiders sold a total of 28,355 shares of company stock valued at $2,148,062 over the last ninety days. 3.02% of the stock is currently owned by company insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Tiverton Asset Management LLC purchased a new position in Agios Pharmaceuticals during the second quarter worth $142,000. Strs Ohio purchased a new position in Agios Pharmaceuticals during the second quarter worth $179,000. NewSquare Capital LLC purchased a new position in Agios Pharmaceuticals during the second quarter worth $182,000. Barrett Asset Management LLC purchased a new position in Agios Pharmaceuticals during the second quarter worth $253,000. Finally, Nisa Investment Advisors LLC purchased a new position in Agios Pharmaceuticals during the third quarter worth $358,000. 93.59% of the stock is owned by hedge funds and other institutional investors.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.
Recommended Story: What is a put option?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.